Accelerate Diagnostics Stock Fundamentals
| AXDX Stock | USD 1.70 0.13 8.28% |
Accelerate Diagnostics fundamentals help investors to digest information that contributes to Accelerate Diagnostics' financial success or failures. It also enables traders to predict the movement of Accelerate Stock. The fundamental analysis module provides a way to measure Accelerate Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Accelerate Diagnostics stock.
At this time, Accelerate Diagnostics' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 8.1 M in 2024, whereas Gross Profit is likely to drop slightly above 1.6 M in 2024. Accelerate | Select Account or Indicator |
Accelerate Diagnostics Company Shares Owned By Insiders Analysis
Accelerate Diagnostics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Accelerate Diagnostics Shares Owned By Insiders | 40.60 % |
Most of Accelerate Diagnostics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Accelerate Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 40.605% of Accelerate Diagnostics are shares owned by insiders. This is 167.49% higher than that of the Life Sciences Tools & Services sector and 161.13% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Accelerate Diagnostics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Accelerate Diagnostics's current stock value. Our valuation model uses many indicators to compare Accelerate Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Accelerate Diagnostics competition to find correlations between indicators driving Accelerate Diagnostics's intrinsic value. More Info.Accelerate Diagnostics is rated below average in return on asset category among its peers. It also is rated below average in operating margin category among its peers . At this time, Accelerate Diagnostics' Operating Profit Margin is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Accelerate Diagnostics' earnings, one of the primary drivers of an investment's value.Accelerate Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Accelerate Diagnostics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Accelerate Diagnostics could also be used in its relative valuation, which is a method of valuing Accelerate Diagnostics by comparing valuation metrics of similar companies.Accelerate Diagnostics is currently under evaluation in shares owned by insiders category among its peers.
Accelerate Fundamentals
| Return On Asset | -0.76 | ||||
| Operating Margin | (2.88) % | ||||
| Current Valuation | 79.38 M | ||||
| Shares Outstanding | 25.04 M | ||||
| Shares Owned By Insiders | 40.60 % | ||||
| Shares Owned By Institutions | 17.45 % | ||||
| Number Of Shares Shorted | 525.17 K | ||||
| Price To Earning | (15.18) X | ||||
| Price To Sales | 3.21 X | ||||
| Revenue | 12.06 M | ||||
| Gross Profit | 3.3 M | ||||
| EBITDA | (49.77 M) | ||||
| Net Income | (61.62 M) | ||||
| Cash And Equivalents | 36.77 M | ||||
| Cash Per Share | 0.45 X | ||||
| Total Debt | 39.22 M | ||||
| Debt To Equity | 2.76 % | ||||
| Current Ratio | 4.48 X | ||||
| Book Value Per Share | (1.36) X | ||||
| Cash Flow From Operations | (40.2 M) | ||||
| Short Ratio | 7.77 X | ||||
| Earnings Per Share | (2.59) X | ||||
| Price To Earnings To Growth | (0.55) X | ||||
| Target Price | 1.5 | ||||
| Number Of Employees | 134 | ||||
| Beta | 0.6 | ||||
| Market Capitalization | 39.32 M | ||||
| Total Asset | 31.37 M | ||||
| Retained Earnings | (668.86 M) | ||||
| Working Capital | 12.43 M | ||||
| Current Asset | 91.68 M | ||||
| Current Liabilities | 4.45 M | ||||
| Net Asset | 31.37 M |
About Accelerate Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Accelerate Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Accelerate Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Accelerate Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.5 M | 1.6 M | |
| Total Revenue | 12.1 M | 12.7 M | |
| Cost Of Revenue | 9.5 M | 7 M | |
| Stock Based Compensation To Revenue | 0.45 | 0.42 | |
| Sales General And Administrative To Revenue | 80.38 | 84.40 | |
| Research And Ddevelopement To Revenue | 2.10 | 2.00 | |
| Capex To Revenue | 0.09 | 0.08 | |
| Revenue Per Share | 0.97 | 1.65 | |
| Ebit Per Revenue | (4.48) | (4.70) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.